REXAHN PHARMACEUTICALS, INC. Uncategorized Contracts & Agreements
29 Contracts & Agreements
- Offer Letter entered into on November 20, 2023 by and between Ocuphire Pharma, Inc. and Joseph Schachle (Filed With SEC on November 27, 2023)
- First Amendment to 2021 Inducement Plan (Filed With SEC on November 1, 2023)
- Ocuphire Pharma, Inc. 2020 Inducement Plan (Filed With SEC on March 11, 2021)
- Form of Lock-Up Agreement, by and between the Company, OcuSub, Inc. and certain stockholders (Filed With SEC on March 11, 2021)
- Description of Securities (Filed With SEC on March 11, 2021)
- Form of Indemnity Agreement between the Company and each of its directors and executive officers (Filed With SEC on November 6, 2020)
- First Amendment to Sublicense Agreement, dated as of June 4, 2020, by and between Apexian Pharmaceuticals, Inc. and Ocuphire Pharma, Inc (Filed With SEC on July 6, 2020)
- Sublicense Agreement, dated as of January 21, 2020, by and between Ocuphire Pharma, Inc. and Apexian Pharmaceuticals, Inc (Filed With SEC on July 6, 2020)
- Stockholders Agreement, dated as of April 10, 2018, among Ocuphire Pharma, Inc. and Stockholders as defined therein (Filed With SEC on July 6, 2020)
- Form of Leak-Out Agreement, by and between Rexahn and the investors party thereto (Filed With SEC on July 1, 2020)
- Form of Series A/B Warrants (Filed With SEC on July 1, 2020)
- Form of Leak-Out Agreement, by and between Rexahn and the investors party thereto (Filed With SEC on June 19, 2020)
- Form of Lock-Up Agreement, by and among Rexahn, Ocuphire and certain stockholders of Rexahn and Ocuphire (Filed With SEC on June 19, 2020)
- Form of CVR Agreement, by and among Rexahn, the CVR Representative, and the Rights Agent (Filed With SEC on June 19, 2020)
- Form of Series A/B Warrants (Filed With SEC on June 19, 2020)
- Engagement Letter, dated as of October 16, 2018, by and between Rexahn Pharmaceuticals, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on October 19, 2018)
- Engagement Letter, dated as of October 12, 2017, by and between Rexahn Pharmaceuticals, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on October 13, 2017)
- Engagement Letter, dated as of June 5, 2017 by and between Rexahn Pharmaceuticals, Inc. and Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLC (Filed With SEC on June 7, 2017)
- Engagement Letter, dated as of September 13, 2016 by and between Rexahn Pharmaceuticals, Inc and Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLC (Filed With SEC on September 14, 2016)
- Engagement Letter, dated as of February 26, 2016 by and between Rexahn Pharmaceuticals, Inc and Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLC (Filed With SEC on February 26, 2016)
- Engagement Letter, dated as of November 5, 2015, by and between Rexahn Pharmaceuticals, Inc and Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLC (Filed With SEC on November 6, 2015)
- Engagement Letter, dated as of January 14, 2014, by and between Rexahn Pharmaceuticals, Inc. and Roth Capital Partners, LLC (Filed With SEC on January 15, 2014)
- Engagement Letter, dated as of October 10, 2013, by and between Rexahn Pharmaceuticals, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on October 16, 2013)
- H.C. Wainwright & Co., LLC 570 Lexington Avenue, New York, New York 10022 ###-###-#### www.hcwco.com Member: FINRA, SIPC 1 (Filed With SEC on July 24, 2013)
- Engagement letter, dated as of March 23, 2011, as amended on March 29, 2011, by and between Rexahn Pharmaceuticals, Inc. and Rodman & Renshaw, LLC (Filed With SEC on March 30, 2011)
- Engagement letter, dated as of June 27, 2010, by and between Rexahn Pharmaceuticals, Inc. and Rodman & Renshaw, LLC (Filed With SEC on June 29, 2010)
- Engagement letter, dated as of October 19, 2009, by and between Rexahn Pharmaceuticals, Inc. and Rodman & Renshaw, LLC (Filed With SEC on October 20, 2009)
- Amendment to engagement letter, dated as of May 19, 2009, by and between Rexahn Pharmaceuticals, Inc. and Rodman & Renshaw, LLC (Filed With SEC on May 20, 2009)
- Engagement letter, dated as of April 6, 2009, by and between Rexahn Pharmaceuticals, Inc. and Rodman & Renshaw, LLC (Filed With SEC on May 20, 2009)
